Hepatocellular carcinoma （HCC）is a malignant tumor with high morbidity and mortality， which has no obvious symptoms in the early stage. At the time of diagnosis ，most patients are already in the advanced stage and cannot receive radical surgery. Molecular targeted drugs represented by sorafenib are the stan⁃ dard treatment for advanced HCCbut the efficacy is still not ideal. In recent years，immunotherapy represented by immune checkpoint inhibitors （ICIs）achieved remarkable results in advanced HCC. This article wouldbriefly review the clinical research status of ICIs in advanced HCC.